A handheld, saliva-based diagnostic device that detects 8 cancer biomarkers in under 15 minutes — no needles, no labs, no waiting.
8 biomarkers analyzed · 14m 38s
Early detection saves lives, but current methods create barriers that millions of Egyptians simply cannot overcome.
63% of patients experience needle phobia, leading to systematic avoidance of essential blood tests, vaccinations, and cancer screening programs.
Tumor marker tests cost EGP 3,500–5,000. PET scans reach EGP 7,000. For most Egyptians, early detection is financially out of reach.
By the time symptoms appear, cancer is often Stage III or IV. 2 million patients drop out of MRI scans annually due to anxiety and access barriers.
Proteometer brings laboratory-grade cancer screening to the point of care — clinics, screening camps, and eventually homes — at a fraction of the current cost.
Every layer of the biosensor is optimized for sensitivity, specificity, and real-world saliva matrix conditions.
Electrodeposited gold nanoparticles increase electrode surface area 15×, enabling femtogram-level biomarker detection in saliva.
Antibodies are Fc-captured, leaving both antigen-binding arms free — 2.5× more effective than random attachment methods.
50 nm size-exclusion membrane blocks salivary mucins while allowing 10–50 kDa target biomarkers to reach the sensor.
STM32 microcontroller runs signal processing and trend analysis locally — no cloud required for point-of-care screening.
Proteometer isn't a one-time test — it's a continuous monitoring ecosystem that transforms screening data into actionable health journeys.
Building an ecosystem of healthcare providers, manufacturers, and government stakeholders to deliver screening at national scale.
Egypt's presidential program for early cancer detection. Our 4-cancer panel directly aligns with their national screening mandate.
Partnership ActivePrimary clinical validation site for our 50-patient pilot study, with access to oncology, pathology, and biomedical engineering labs.
Partnership ActiveNanotechnology lab access for biosensor fabrication scale-up and roll-to-roll manufacturing process research.
In DiscussionSeeking ISO 13485-certified partners for PCB assembly, injection molding, and sterile packaging at scale.
Target Q3 2026Medical supply distributors in KSA, UAE, and Morocco for Phase 2 geographic expansion beyond Egypt.
Target 2027HIPAA/GDPR-compliant hosting for patient data vault, AI model training, and population health analytics.
In DiscussionReal-time connectivity between patients, physicians, and public health systems — seamlessly integrated.
Encrypted messaging for result explanation, referral coordination, and follow-up care planning.
Your CEA levels are stable. Continue annual screening.
Thank you doctor. Should I adjust my diet?
Anonymized, real-time epidemiological data for the Ministry of Health and Population.
RESTful API for EHR integration, insurance claims, and third-party diagnostic platforms.
Video modules, certification quizzes, and device troubleshooting for healthcare workers.
From bench to bedside — our phased approach to regulatory approval and clinical adoption.
Biosensor fabrication protocol validated at MNU labs. AuNP roughness factor 15× achieved. Baseline EIS reproducibility CV < 8%.
PCB potentiostat assembly, STM32 firmware, and 3D-printed reader enclosure. Target completion: May 2026.
Prospective cohort at Mansoura University Hospital. Sensitivity/specificity validation vs. ELISA and imaging gold standards.
ISO 13485 quality management system implementation. Clinical performance dossier preparation and regulatory filing.
Multi-site study for EDA Class III medical device registration. Manufacturing scale-up initiation in parallel.
Commercial rollout via 100M Health Initiative channels. MENA expansion planning begins Q2 2028.
Whether you are a healthcare provider, investor, or government stakeholder — partner with us to bring early cancer detection to every community in Egypt and beyond.